SPAF

Stroke Prevention in Atrial Fibrillation Study

Patient / Population Intervention / Exposition Vergleich Endpunkt

In 1,330 patients with non-rheumatic atrial fibrillation, warfarin and aspirin each reduced ischaemic stroke or systemic embolism compared with placebo.

1.330

Design

Multicentre RCT (warfarin/aspirin vs placebo)

Endpunkt

Ischaemic stroke or systemic embolism

Relevanz

ErgebnisAspirin 3.6%/yr vs placebo 6.3%/yr (42% risk reduction, 95% CI 9-63%; P=0.02). Warfarin reduced events by 67% vs placebo (95% CI 27-85%; P=0.01). Both positive.

Stroke Prevention in Atrial Fibrillation Investigators. Circulation. 1991;84(2):527-539. 10.1161/01.CIR.84.2.527

Diskussion & Kritik

Short follow-up and stratified design without head-to-head warfarin-versus-aspirin randomisation across all patients. Landmark evidence establishing antithrombotic therapy for stroke prevention in atrial fibrillation.